Rasagiline Viatris (previously Rasagiline Mylan) (rasagiline)
Generic
- Region
- 🇪🇺 EU
- Active substance
- rasagiline
- Company
- Viatris Limited
- Status
- Authorised
- Therapeutic area
- Parkinson Disease
- CHMP opinion
- Thu 28 Jan 2016
- EU approval
- Mon 04 Apr 2016
- Designations
- Generic
- Application
- EMEA/H/C/004064
- ATC
- N04BD02
- Official record
- www.ema.europa.eu
Indication
Rasagiline Viatris is indicated for the treatment of idiopathic Parkinson’s disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Azilect Authorised · Teva B.V.
- 🇪🇺 Rasagiline ratiopharm Authorised · Teva B.V.
Follow Rasagiline Viatris (previously Rasagiline Mylan)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.